Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microwave ablation with or without PD-1 immunotherapy for synchronous multiple primary lung cancer
ChiCTR2000036613Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab in multiple primary lung cancer (MPLC) and bronchial carcinoma (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Disease-free survival at 2 years, Disease-free survival at 3 years and 2 more. Started Apr 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
multiple primary lung cancer (MPLC)bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2000036613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036613.